Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 9/20 | 0.38 |
| ▸ | GAK | O14976 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26329960 | 0.81 | ALDH1A1 (0.47) | NTSR1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL26329863 | 0.81 | LRRK2 (0.44) | LRRK2SYKGAK | |
| SCHEMBL26329904 | 0.80 | MTOR (0.39) | NTSR1GAK | |
| SCHEMBL26329889 | 0.80 | GAK (0.38) | SYKGAKNPSR1MEN1NPC1 | |
| SCHEMBL26317987 | 0.76 | MAPT (0.41) | NTSR1TSHRNPSR1MEN1NPC1 | |
| SCHEMBL26317976 | 0.73 | TSHR (0.50) | NTSR1GAKTSHRNPSR1MEN1 | |
| SCHEMBL25826546 | 0.73 | LMNA (0.46) | SYKTSHRNPSR1MEN1NPC1 | |
| SCHEMBL24004017 | 0.72 | TSHR (0.60) | GAKTSHRNPSR1MEN1NPC1 | |
| SCHEMBL25466142 | 0.72 | KDM4E (0.43) | LRRK2MEN1NPC1MAPTRAB9A | |
| SCHEMBL26317979 | 0.71 | IDH1 (0.41) | LRRK2SYKNTSR1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | LRRK2 507/4885SYK 1989/4885NTSR1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.